Targacept, a biopharmaceutical company developing a new class of drugs to treat central nervous system and other diseases, filed an S-1 registration statement for the second time. The Winston-Salem, NC based firm tried to go public in February 2005 but withdrew the offering on March of the same year citing difficult market conditions. Deutsche Bank Securities, Pacific Growth Equities, CIBC World Markets and Lazard are the underwriters for the deal. Terms and timing have yet to be announced.
